SouthState Bank Corp reduced its holdings in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 99.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 395 shares of the company’s stock after selling 63,327 shares during the quarter. SouthState Bank Corp’s holdings in Astrazeneca were worth $78,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in AZN. Triumph Capital Management bought a new stake in Astrazeneca during the third quarter worth about $25,000. MV Capital Management Inc. acquired a new stake in Astrazeneca in the 4th quarter valued at about $26,000. Mascoma Wealth Management LLC bought a new position in Astrazeneca during the first quarter worth about $26,000. Bangor Savings Bank increased its position in Astrazeneca by 102.7% during the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after buying an additional 154 shares during the last quarter. Finally, Eagle Bay Advisors LLC acquired a new stake in shares of Astrazeneca in the fourth quarter valued at approximately $30,000. Institutional investors and hedge funds own 20.35% of the company’s stock.
Astrazeneca Stock Performance
Astrazeneca stock opened at $169.08 on Friday. The stock has a market cap of $262.23 billion, a PE ratio of 25.39, a P/E/G ratio of 1.37 and a beta of 0.24. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a 12-month low of $137.23 and a 12-month high of $212.71. The business’s 50-day moving average price is $182.44 and its two-hundred day moving average price is $188.47.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on AZN shares. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a research note on Friday, June 26th. Barclays reiterated a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. The Goldman Sachs Group restated a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Finally, Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $211.00.
Get Our Latest Research Report on Astrazeneca
Astrazeneca Company Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Featured Stories
- Five stocks we like better than Astrazeneca
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
